
    
      The maximum study duration was up to approximately 54 weeks per participants:

        -  Up to 2-week screening period

        -  6-month open-label comparative efficacy and safety treatment period

        -  6-month open-label comparative safety extension period

        -  48-hour post-treatment safety follow-up period
    
  